CNTNAP3P2

Across TCGA pan-cancer cohorts, CNTNAP3P2 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CNTNAP3P2 data layer compared with 19 for mass-spec protein.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher CNTNAP3P2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated CNTNAP3P2 expression acts as an unfavorable survival marker.

COAD, PRAD, and BLCA are the cancer types where CNTNAP3P2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	DFS	Median	All	0.140	0.783	<.001	18	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
BLCA	DFS	Median	III,IV	0.139	0.572	.026	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

CNTNAP3P2–COAD (DFS)

Open the COAD breakdown →